Our Portfolio

Deerfield portfolio companies strive to advance healthcare in meaningful and innovative ways.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Industry
Clear
Purpose of Financing
Clear
Stage
Clear
Structure of Financing
Clear
Status of Investment
Clear
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tag
:
Tag
Showing 0 of 100
Epic Sciences
Epic Sciences
Medical Technologies
Aug 2018
Growth
Late Stage
Equity
Current
Element Science
Element Science
Medical Technologies
Aug 2019
Venture
Mid Stage
Equity
Current
Elion Therapeutics
Elion Therapeutics
Therapeutics
Jan 2019
Venture
Seed/Startup
Equity
Current
Elutia
Elutia
Medical Technologies
Nov 2015
Special Situations
Growth
Equity
Current
Encodia
Encodia
Medical Technologies
Dec 2020
Venture
Early Stage
Equity
Current
Deerfield Catalyst
Deerfield Catalyst
Medical Technologies
Jan 2021
Venture
Seed/Startup
Equity
Current
Dracen Pharmaceuticals
Dracen Pharmaceuticals
Therapeutics
Jan 2018
Venture
Mid Stage
Equity
Current
Cystetic Medicines
Cystetic Medicines
Therapeutics
Nov 2020
Venture
Seed/Startup
Equity
Current
CVAUSA
CVAUSA
Healthcare Services
Apr 2023
Current
COTA Healthcare
COTA Healthcare
Healthcare Services
Oct 2022
Growth
Late Stage
Debt and Equity
Current
Crossover Health Management Services
Crossover Health Management Services
Healthcare Services
Mar 2021
Growth
Late Stage
Equity
Current
Cortica
Cortica
Healthcare Services
Apr 2023
Current
Cohere Health
Cohere Health
Healthcare Services
Mar 2021
Venture
Mid Stage
Equity
Current
CathWorks
CathWorks
Medical Technologies
Feb 2019
Growth
Late Stage
Equity
Current
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics
Therapeutics
Apr 2024
Special Situations
Mid Stage
Equity
Current
DISCLAIMER

The portfolio companies shown represents a significant portion of the current portfolio of Deerfield funds utilizing the Private Design Strategy or Healthcare Innovations Strategy.  Exclusions include historical investments, research projects and related entities, companies in stealth mode, companies without material operations, companies in which Deerfield funds hold residual interests, investments in other funds, and investment portfolios of other Deerfield strategies. The specific portfolio companies identified are not representative of all of the portfolio companies purchased, sold, or recommended for Deerfield funds, and it should not be assumed that any investment in an identified portfolio company was or will be profitable. Actual holdings will vary for each Deerfield fund and there is no guarantee that a particular Deerfield fund will hold any or all of the portfolio companies listed.